Aktis Oncology, Inc. (AKTS)

Aktis Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	180.25	37.16	29.51	128.6
Short-Term Investments	65.97	260.01	68.35	-
Cash & Short-Term Investments	246.22	297.17	97.86	128.6
Cash Growth	91.47%	203.66%	-23.90%	-
Other Receivables	0.9	1.1	0.3	-
Receivables	0.9	1.1	0.3	-
Prepaid Expenses	2.3	2.59	2.04	3.88
Total Current Assets	249.42	300.85	100.2	132.48
Property, Plant & Equipment	24.3	20.87	20.92	4.87
Other Long-Term Assets	5.32	4.46	1.23	0.98
Total Assets	279.04	326.18	122.36	138.32
Accounts Payable	2.36	1.92	0.96	0.49
Accrued Expenses	7.1	6.33	3.75	3.93
Current Portion of Leases	1.37	1.3	1.53	0.85
Current Unearned Revenue	16.08	9.28	-	-
Total Current Liabilities	26.91	18.82	6.24	5.28
Long-Term Leases	10.5	10.71	11.87	0.92
Long-Term Unearned Revenue	40.61	51.04	-	-
Other Long-Term Liabilities	-	-	0.5	1.31
Total Liabilities	78.02	80.58	18.61	7.5
Additional Paid-In Capital	9.02	4.91	2.47	0.98
Retained Earnings	-141.43	-92.83	-48.85	-20.21
Comprehensive Income & Other	0.02	0.12	0.08	-
Total Common Equity	-132.39	-87.8	-46.31	-19.23
Shareholders' Equity	201.02	245.61	103.74	130.82
Total Liabilities & Equity	279.04	326.18	122.36	138.32
Total Debt	11.87	12.01	13.4	1.78
Net Cash (Debt)	234.36	285.16	84.46	126.82
Net Cash Growth	84.79%	237.63%	-33.40%	-
Net Cash Per Share	295.38	404.96	137.29	245.11
Filing Date Shares Outstanding	0.82	0.78	0.65	0.52
Total Common Shares Outstanding	0.82	0.78	0.65	0.52
Working Capital	222.51	282.03	93.97	127.21
Book Value Per Share	-162.43	-112.42	-71.27	-37.17
Tangible Book Value	-132.39	-87.8	-46.31	-19.23
Tangible Book Value Per Share	-162.43	-112.42	-71.27	-37.17
Machinery	11.73	8.81	6.4	2.74
Construction In Progress	3.96	1.33	0.4	0.56
Leasehold Improvements	0.17	0.17	0.17	0.17

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q